论文部分内容阅读
为提高抗癌药物对癌细胞或组织的靶向性,增强疗效,降低其全身毒副作用,以不同材料作载体的抗癌药物微球相继研制成功:不可生物降解的乙基纤维素微球,可生物降解的白蛋白微球、淀粉微球、明胶微球、聚乳酸微球,以及近年来问世的磁性微球、毫微球等。白蛋白微球以其良好的生物相容性和可降解性被广泛用于抗癌药靶向给药系统。 白蛋白微球最初用于动物及人的肺部扫描和循环系统研究,自1974年首次作为抗癌药物载体以来,相继用作诊断试剂及靶向给药、化学栓塞治疗的载体。1 抗癌药物动脉栓塞白蛋白微球 肿瘤动脉栓塞疗法是将抗癌药物制剂选择性注入支配
In order to improve the targeting of anticancer drugs to cancer cells or tissues, enhance the curative effect and reduce their systemic side effects, anticancer drug microspheres made of different materials have been successfully developed: non-biodegradable ethylcellulose microspheres, Biodegradable albumin microspheres, starch microspheres, gelatin microspheres, polylactic acid microspheres, and in recent years the advent of magnetic microspheres, nanospheres and so on. Albumin microspheres are widely used in anticancer drug targeted delivery systems for their good biocompatibility and biodegradability. Albumin microspheres were originally used in animal studies and human lung scans and circulatory system studies. Since they were first used as anticancer drug carriers in 1974, albumin microspheres have been used as diagnostic agents and as carriers for targeted drug delivery and chemoembolization. 1 anticancer drugs arterial embolism albumin microsphere tumor arterial embolization therapy is the selective injection of anticancer drug agents dominated